Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Zenocutuzumab & Biliary tract cancer / Cholangiocarcinoma (NGR1+)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Approval status

On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco for adults with advanced, unresectable or metastatic Biliary tract cancer / Cholangiocarcinoma (NGR1+) with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.
AACR FDA Approval Alert 2026/08/05

see also:
Anti HER2/HER3 antibodies & Biliary tract cancer / Cholangiocarcinoma (NGR1+)
[Biliary tract cancer / Cholangiocarcinoma (NGR1+) & Drugs/Treatments](brain://Ye_IVDIFwECOd6H3zkupDA/BiliaryTractCa…

AI Chat

7/2/2026

Chat with our artificial intelligence:

Start chat!

Zenocutuzumab & Biliary tract cancer / Cholangiocarcinoma (NGR1+)

Welcome to meRfi Microbiome!

Navigation

Contents

Approval status

AI Chat